{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:52:11Z","timestamp":1766753531540,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A2B4007282"],"award-info":[{"award-number":["NRF-2016R1A2B4007282"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clml.2019.03.023","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T22:18:09Z","timestamp":1553897889000},"page":"345-355.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-8200","authenticated-orcid":false,"given":"Young-Woo","family":"Jeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seugyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.023_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ctrv.2007.02.002","article-title":"High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis","volume":"33","author":"Greb","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2019.03.023_bib2","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.023_bib3","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen","volume":"21","author":"Urbano-Ispizua","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PPO.0b013e31826b124c","article-title":"Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma","volume":"18","author":"Khouri","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2019.03.023_bib6","article-title":"Allogeneic transplantation after myeloablative rituximab\/BEAM \u00b1 bortezomib for patients with relapsed\/refractory lymphoid malignancies: 5-year follow-up results","volume":"19","author":"Chamoun","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib7","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib11","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib12","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2005-02-0596","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.2201","article-title":"Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas","volume":"35","author":"Yoon","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.023_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","article-title":"Allotransplantation for patients age\u00a0\u2265 40 years with non-Hodgkin lymphoma: encouraging progression-free survival","volume":"20","author":"McClune","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib25","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbmt.2005.04.005","article-title":"Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma","volume":"11","author":"Dean","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2006.10.015","article-title":"Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives","volume":"13","author":"Sandmaier","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib29","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib31","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","article-title":"The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia","volume":"16","author":"Russell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2007.15.8865","article-title":"Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Rodrigues","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.023_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.023_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/TP.0b013e318256dcba","article-title":"Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?","volume":"94","author":"Peterlin","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2019.03.023_bib37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbmt.2011.12.581","article-title":"Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure","volume":"18","author":"Freytes","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bmt.2014.293","article-title":"Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation","volume":"50","author":"Nakasone","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.03.023_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2013.140","article-title":"Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"48","author":"Kanamori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib41","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2015.174","article-title":"Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies","volume":"50","author":"Yerushalmi","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.023_bib42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2017.01.079","article-title":"Human leukocyte antigen-haploidentical transplantation for relapsed\/refractory Hodgkin lymphoma: a multicenter analysis","volume":"23","author":"Lacerda","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501831677X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501831677X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:26Z","timestamp":1761870806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501831677X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S215226501831677X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.023","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}